Acute decompensated heart failure: Formulating an evidence-based approach to diagnosis and treatment (Part I)

Mount Sinai Journal of Medicine

Volumn 73, Issue 2, 2006, Pages 506-515

  Chung, Philip ^a   Hermann, Luke ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Acute decompensated heart failure; Natriuretic peptides; Neurohormones; Vasodilator response

Indexed keywords

ALDOSTERONE; ANGIOTENSIN; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT; ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENDOTHELIN; NATRIURETIC PEPTIDE TYPE C; NITRATE; NORADRENALIN; RENIN; SPIRONOLACTONE; VASODILATOR AGENT; VASOPRESSIN;

ACUTE HEART FAILURE; ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DYSPNEA; ELECTROCARDIOGRAM; EVIDENCE BASED MEDICINE; HEART INFARCTION; HEART PERFORMANCE; HUMAN; INCIDENCE; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PRACTICE GUIDELINE; PREDICTION; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; THORAX RADIOGRAPHY;

ACUTE DISEASE; CARDIOTONIC AGENTS; DISEASE PROGRESSION; DYSPNEA; EMERGENCY SERVICE, HOSPITAL; EVIDENCE-BASED MEDICINE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDES; NEUROTRANSMITTER AGENTS; VASODILATION;

EID: 33645033481     PISSN: 00272507     EISSN: 00272507     Source Type: Journal    
DOI: None     Document Type: Article

References (69)

1. American Heart Association. Heart disease and stroke statistics - 2004 update. Dallas, TX: American Heart Association; 2003.
2. National Center for Health Statistics. National hospital discharge survey 2001. http://www.cdc.gov/nchs/data/hdasd/sr13_156t11.pdf.
3. American Heart Association. Heart Disease and Stroke Statistics - 2005 update. Dallas, TX: American Heart Association; 2005.
4. Jong P, Vowinckel E, Liu PP, et al. Prognosis and determinants of survival in patients newly hospitalized for heart failure: a population based study. Arch Intern Med 2002; 162(15):1689.
5. ADHERETM Registry [database]. First quarter 2003 benchmark report. Sunnyvale, CA: Scios, Inc; Jan 2003.
6. Peterson ED, Pollack CV Jr, Roe MT, et al. Early use of glycoprotein IIb/ IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4. J Am Coll Cardiol 2003; 42(1):45-53.
7. Daley J, Jencks S, Draper D, et al. Predicting hospital-associated mortality for Medicare patients. A method for patients with stroke, pneumonia, acute myocardial infarction, and congestive heart failure. JAMA 1988; 260:3617-3624.
8. Fonarow GC, Adams KF, Abraham WT, et al. Risk stratification for in-hospital mortality in acutely decompensated heart failure. JAMA 2005; 293(5):572-580.
9. Packer M. How should physicians view heart failure? The philosophical and physiological evolution of three conceptual models of the disease. Am J Cardiol 1993; 71:3C-11C.
10. Mann DL. Mechanisms and models in heart failure: a combinatorial approach. Circulation 1999; 100(9):999-1008.
11. Francis GS, Siegel RM, Goldsmith SR, et al. Acute vasoconstrictor response to intravenous furosemide in chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985; 103(1):1-6.
12. Mills RM. The failing heart and the hemodynamic response to vasodilator therapy. Clin Cardiol 2003; 26(6):257-258.
13. Braunwald, E. Pathophysiology of heart failure. In: Braunwald E, editor. Heart disease. 4th ed. Philadelphia: Saunders; 1992. p. 393.
14. Strauss RH, Stevenson LW, Dadourian BA, et al. Predictability of mitral regurgitation detected by Doppler echocardiography in patients referred for cardiac transplantation. Am J Cardiol 1987; 59:892-894.
15. Weiland DS, Konstam MA, Salem DN, et al. Contribution of reduced mitral regurgitant volume to vasodilator effect in severe left ventricular failure secondary to coronary artery disease or idiopathic dilated cardiomyopathy. Am J Cardiol 1986; 58:1046-1050.
16. Stevenson LW, Bellil D, Grover-McKay M, et al. Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987; 60:654-658.
17. Aggarwal A. Esler MD, Socratous F, Kaye DM. Evidence for functional presynaptic alpha-2 adrenoceptors and their down-regulation in human heart failure. J Am Coll Cardiol 2001; 37(5):1246-1251.
18. MacCarthy PA, Grocott-Mason R, Prendergast BD, Shah AM. Contrasting ionotropic effects of endogenous endothelin in the normal and failing human heart: studies with an intracoronary ET(A) receptor antagonist. Circulation 2000; 101(2):142-147.
19. Dzau VJ. Renal and circulatory mechanisms in congestive heart failure. Kidney Int 1987; 31(6):1402-1415.
20. Benedict CR, Johnstone DE, Weiner DH, et al. Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. J Am Coll Cardiol 1994; 23(6):1410-1420.
21. Dzau VJ, Colucci WS, Hollenberg NK, Williams GH. Relation of the renin-angiotensin-aldosterone system to clinical state in congestive heart failure. Circulation 1981; 63(3):645-651.
22. Mizuno Y, Yoshimura M, Yasue H, et al. Aldosterone production is activated in failing ventricle in humans. Circulation 2001; 103(1):72-77.
23. Kawano H, Do YS, Kawano Y, et al. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101(10):1130-1137.
24. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32(6):865-875.
25. Pieske B, Beyermann B, Breu V, et al. Functional effects of endothelin and regulation of endothelin receptors in isolated human failing and nonfailing myocardium. Circulation 1999; 99(14):1802-1809.
26. Lee WH, Packer M. Prognostic importance of serum sodium concentration and its modification by converting-enzyme inhibition in patients with severe congestive heart failure. Circulation 1986; 73(2):257-267.
27. Cohn, JN, Levine TB, Olivaro MT, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984; 311(13):819-823.
28. Aronson D, Burger A. Neurohormonal prediction of mortality following admission for decompensated heart failure. Am J Cardiol 2003; 91 (2):245-248.
29. Flather MD, Yusuf S, Kober L, et al. Long-term ACE-inbibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355(9215):1575-1581.
30. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341(10):709-717.
31. Foody JM, Farrell MH, Krumholz HM. Beta-blocker therapy in heart failure: scientific review. JAMA 2002; 287(7):883-889.
32. Kinnunen P, Vuolteenaho O, Ruskoaho H. Mechanisms of atrial and brain natriuretic peptide release from rat ventricular myocardium: effect of stretching. Endocrinology 1993; 132(5):1961-1970.
33. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med 1998; 339(5):321-328.
34. Jensen KT, Carstens J, Pederson EB. Effect of BNP on renal hemodynamics, tubular function and vasoactive hormones in humans. Am J Physiol 1998; 274(Suppl):F63-F72.
35. Abraham WT, Lowes BD, Ferguson DA, et al. Systemic, hemodynamic, neurohormonal and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure. J Card Fail 1998; 4:37-44.
36. Kohno M, Yokokawa K, Horio T, et al. Atrial and brain natriuretic peptide inhibit the endothelin-1 secretory response to angiotensin II in porcine aorta. Circ Res 1992; 70:241-247.
37. Akabane S, Matsushima Y, Matsuo H, et al. Effects of brain natriuretic peptide on renin secretion in normal and hypertonic saline-infused kidney. Eur J Pharmacol 1991; 198:143-148.
38. Abramson BL, Shin-ichi A, Notarius CF, et al. Effect of atrial natriuretic peptide on muscle sympathetic activity and its control in human heart failure. Circulation 1999; 99:1810-1815.
39. Badgett, RG, Lucey CR, Mulrow CD. Can the clinical examination diagnose left-sided heart failure in adults? JAMA 1997; 277(21): 1712-1719.
40. Stevenson LW, Perloff JK, The limited reliability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261(6):884-888.
41. Davie AP, Francis CM, Caruana L, et al. Assessing diagnosis in heart failure: which features are of any use? Q J Med 1997; 90:335-339.
42. Silver MT, Rose GA, Paul SD, et al. A clinical rule to predict preserved left ventricular ejection fraction in patients after myocardial infarction. Ann Intern Med 1994; 121(10):750-756.
43. Stevenson LW, Perloff JK. The limited reliability of the physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261(6):884-888.
44. Knudsen CW, Omland T, Clopton P, et al. Diagnostic value of B-type natriuretic peptide and chest radiographic findings in patients with acute dyspnea. Am J Med 2004; 116:363-368.
45. Mahdyoon H, Klein R, Eyler W, et al. Radiographic pulmonary congestion in end-stage congestive heart failure. Am J Cardiol 1999; 63(9):625-627.
46. Kruger S, Filzmaier K, Graf J, et al. QRS Prolongation on surface ECG and brain natriuretic peptide as indicators of left ventricular systolic dysfunction. J Intern Med 2004; 255(2):206-212.
47. Ho KK, Anderson KM, Kannel WB, et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation 1993; 88(1):107-115.
48. McKee PA, Castelli WP, McNamara PM, Kannel WB. The natural history of congestive heart failure: the Framingham study. N Eng J Med 1971; 285(26):1441-1446.
49. Davis M, Espiner E, Richards G, et al. Plasma brain natriuretic peptide in assessment of acute dyspnea. Lancet 1994; 343:440-444.
50. Dao, Q, Krishnaswamy P, Kazanegra R, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Cardiol 2001; 37(2):379-385.
51. McCullough PA, Nowak RM, McCord J, Hollander JE, et al. B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 2002; 106(4):416-422.
52. Munagala VK, Burnett JC, Redfield MM. The natriuretic peptides in cardiovascular medicine. Curr Probl Cardiol 2004; 29(12):707-769.
53. Schwam E. B-type natriuretic peptide for the diagnosis of heart failure in emergency department patients: a critical appraisal. Acad Emerg Med 2004; 11 (6):686-691.
54. Ray P, Arthaud M, Lefort Y, et al. Usefulness of B-type natriuretic peptide in elderly patients with acute dyspnea. Intensive Care Med 2004; 30(12):2230-2236.
55. Cabanes L, Richard-Thiriez B, Fulla Y, et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120(6):2047-2050.
56. Ando T, Ogawa K, Yamaki K, et al. Plasma concentration of atrial, brain, and C-type natriuretic peptides and endothelin-1 in patients with chronic respiratory disease. Chest 1996; 110(2):462-468.
57. Chua G, Kang-Hoe L. Marked elevations in N-terminal brain type natriuretic peptide levels in septic shock. Crit Care 2004; 8:248-250.
58. Cataliotti A, Malatino LS, Jougasaki M, et al. Circulating natriuretic, peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc 2001; 76(11):1111-1119.
59. Winter WE, Elin RJ. The role of ventricular peptides in heart failure. Clin Lab Med 2004; 24:235-274.
60. Fischer Y, Filzmaier K, Stiegler H, et al. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide. Clin Chem 2001; 47(3):591-594.
61. Lainchbury JG, Campbell E, Frampton CM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 2003; 42(4):728-735.
62. Yeo KT, Wu AH, Apple FS, et al. Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triagge BNP assay. Clinica Chimica Acta 2003; 338(1-2):107-115.
63. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000; 355(9210):1126-1130.
64. Richards AM, Nicholls MG, Yandle TG, et al. Neuroendocrine prediction of left ventricular function and heart failure after myocardial infarction. Am Heart J 1999; 81:114-120.
65. Bonarjee VV, Omland T, Nilsen DW, et al. Plasma proatrial natriuretic factor concentration after myocardial infarction: relation to indices of cardiac and renal function. Br Heart J. 1995; 73:511-516.
66. Richards AM, Nicholls MG, Yandle TG, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 1998; 97:1921-1929.
67. Totsune K, Takahashi K, Murakami O, et al. Elevated plasma C-type natriuretic peptide concentrations in patients with chronic renal failure. Clin Sci (Lond) 1994; 87(3):319-322. Erratum in: Clin Sci (Colch) 1994; 87(6):following xxv.
68. Cargill RI, Barr CS, Coutie WJ, et al. C-type natriuretic peptide level in cor pulmonale and congestive heart failure. Thorax 1994; 49(12):1247-1249.
69. Sudoh T, Minamino N, Kangawa K, Matsuo H. C-type natriuretic peptide (CNP): a new member of natriuretic peptide family identified in porcine brain. Biochem Biophys Res Commun 1990; 168(2):863-870.